David Fredrickson, executive vice president of AstraZeneca's oncology business unit (AstraZeneca) There are still more data to come. While the trial has so far shown a “numerically favorable ...

Understand every aspect of the global economy – and know how to make your next move.

The thing that I worry about more than loss of exclusivity is this term that I introduced at the AACR meeting -- loss of relevancy" says Susan Galbraith, EVP of Oncology R&D at AstraZeneca.

AstraZeneca is pushing forward with implementing ... significantly reducing mortality rates over the next two decades. David Fredrickson, the Executive Vice-President of the company's Oncology ...

said AstraZeneca Executive Vice President of Oncology David Fredrickson. The U.S. Food and Drug Administration first approved the drug in 2017 to treat a type of bladder cancer. Imfinzi won ...